Perfil
Alain Klapholz is the founder and currently holds the position of Chief Technical & Financial Officer at OptMed, Inc., a company he founded in 2007.
Mr. Klapholz completed his undergraduate degree at Yeshiva University in 1977 and obtained an MBA from The Leonard N Stern School of Business in 1979.
Cargos activos de Alain Klapholz
| Empresas | Cargo | Inicio |
|---|---|---|
OptMed, Inc.
 OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | Fundador | 01/01/2007 |
Formación de Alain Klapholz.
| Yeshiva University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Alain Klapholz
